NEW YORK -- U.S. antitrust and securities regulators are investigating Biogen's conduct involving its controversial Alzheimer's disease treatment developed in partnership with Japan's Eisai.
Pharmaceuticals
U.S. probes approval of Biogen-Eisai Alzheimer's drug
FTC and SEC seek information from American drugmaker
Japanese drugmaker Eisa's Tokyo headquarters. (Photo by Kosaku Mimura)
Latest on Pharmaceuticals
